Ipsen SA · EURONEXT:IPN
Ipsen SA — JP Morgan 29th Annual Healthcare Conference (January 2011)
18 slides from Ipsen SA's conference presentation, January 2011
Slide 1: Ipsen Update
Ipsen Update JP Morgan - 29th Annual Healthcare conference January 11th,2010 – San Francisco Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only
Slide 2: Ipsen today: a global biotech specialty pharma
Ipsen today : a global biotech specialty pharma… SPECIALTY CARE PRIMARY CARE A global business to GROW OPTIMISE presence ONCOLOGY A transactional model 24% GI 18% Decapeptyl® ENDOCRINOLOGY 20% Cognitive disorders 11% Somatuline®, Nutropin®, Increlex® NEUROLOGY 16% Cardiovascular 7% Dysport® , Apokyn
Slide 3: Specialty care driving the Group's dynamic growth
… and Specialty care driving the Group’s dynamic growth DRUG SALES by therapeutic area GROUP SALES by region (excl. Drug related sales) (incl. Drug related sales) +7.4% +7.0% 411.7 +13.4% 535.4 411.8 (0.3)% 464.8 203.8 175.8 +14.6% 43.9 288.1 (2.4)% 282.3 33.5 +26.3% 156.3 + 13.0% 182.7 9M 2009 9M 2
Slide 4: Today, a reinforced profile / A contrasted 2010
Today, a reinforced profile 2002 2009 2012 illustrative trend Primary Specialist Primary Specialist Primary Specialist Care Care Care Care Care Care ~30% ~70% ~60% ~40% ~38% ~62% Total drug sales: ~€700 m Total drug sales: ~€1 bn Acceleration of growth Confirming Ipsen’s biotech specialty care profi
Slide 5: A truly differentiated R&D
A truly differentiated R&D Expertise applied to well defined disease areas and indications Endocrinology Oncology Neurology Hematology Hormonal • Acromegaly • Hormone- • Neuromuscular • Hemophilia A pathways dependent disorders, • Cushing’s • Hemophilia B cancers: focusing on Peptide & • NET − Prost
Slide 6: Example of differentiation: Somatuline Depot
Example of differentiation : Somatuline® Depot Sandostatin LAR® Somatuline® Autogel® 2.0 ml 0.3 ml – 0.5 ml Administration Intramuscular Subcutaneous Powder vial + solvent filled Presentation Pre-filled syringe syringe + 2 needles 10 steps needed to Ready to use Injection technique reconstitute Self
Slide 7: Dysport indications / A rich and balanced R&D portfolio
Neurology: Dysport® indications Ex North America North America Cervical Dystonia Cervical Dystonia Blepharospasm Aesthetic use Adult Spasticity Cerebral Palsy (pediatric) Adult Spasticity Hyperhydrosis Cerebral Palsy (pediatric) Hemifacial spasm Aesthetic use Current indications 13 Phase III to star
Slide 8: A strong partnership strategy
A strong partnership strategy Ipsen: a long history of partnering activities ENDOCRINOLOGY ONCOLOGY NEUROLOGY PRIMARY CARE 2003 - 2005 2006- 2010 16
Slide 9: Inspiration: A unique offering in haemophilia
Focus on Hemophilia Inspiration : A unique offering in haemophilia : INSPIRATION PRE CLIN PHASE I PHASE II PHASE III EXPECTED FILING DATES IB1001 (FIX) 2011 2012 (acquired) OBI-1 (pFVIII) 2013 (congenital) FVIIa 2014 FVIII 2015 A recombinant product in each segment of the hemophilia market 17 Focus
Slide 10: Progressive path to control of Inspiration
Focus on Hemophilia Progressive path to control of Inspiration. 100% 47% Fully diluted ownership 29%* 8 clinical and regulatory milestones on OBI-1 and IB-1001 20% 2010 Initial equity Total development funding of $174m in Call at market value stake: $85 m exchange for convertible bonds maturing exer
Slide 11: Geographic expansion is part of Ipsen's culture
Geographic expansion is part of Ipsen’s culture… A diversified portfolio in the fastest Currently launching 4 specialty care products growing Eastern European pharma in the world’s largest pharma market market Dysport® Dysport® Decapeptyl® Tanakan® Smectaa® Somatuline® Increlex® Ipsen’s G5 Apokyn® D
Slide 12: US: A tailor made, competitive and complete infrastructure
US presence US : A tailor made, competitive and complete infrastructure… R&D Sales & Marketing 20% of total staff 26% of total staff Boston, MA & Brisbane, CA Brisbane, CA Protein and peptide engineering 60 sales reps covering all major capabilities cities Full development and regulato
Slide 13: A strong and longstanding presence in China
Selected Emerging Markets A strong and longstanding presence in China … Established in 1992 HQ in Tianjin. Total staff of ~ 450 employees ~€75 m 2009 sales Beijing Today, Ipsen’s 2nd largest affiliate TIANJIN Regional sales force teams focused on key coastal cities, now spreading towards t
Slide 14: A strong presence in Russia
Selected Emerging Markets A strong presence in Russia, the fastest growing Eastern European market… Presence since 1993 HQ in Moscow. Total staff of ~200 employees ~€50 m 2009 sales Today, Ipsen’s 7th largest affiliate MOSCOW Sales force regional teams focused on 30+ major cities Strong
Slide 15: Half-year 2010 financial performance
Half-year 2010 financial performance Strong H1 2010 results Drug sales up 6%1 Recurring adjusted2 Operating income up 20.2% Recurring adjusted3 fully diluted EPS (Group share) up 7.1% Solid cash generation: €134.7m generated by operating activities during H1 2010 Solid balance sheet : €142.1m positi
Slide 16: Reminder: Financial objectives for 2010
Reminder : Financial objectives for 2010 Group Drug Sales growth between 3.0 and 5.0% year-on-year Top The Group believes it should be able to deliver on the upper range Line Other Revenues close to €50 million depending on the performance of the Group’s partners EBIT Recurring adjusted1 operating r
Slide 17: Contacts & useful information
Investor Relations contact: Pierre Kemula +33 (0) 1 58 33 60 08 [email protected] Stock info: Outstanding number of shares (December 2010): 84,176,083 Approx. market capitalisation (December 2010): ~€2.1 bn Tickers BBG: IPN FP RTRS: IPN.PA Listing Euronext Paris ADR information Ipsen has a spo
Slide 18: Recurring adjusted operating income
Recurring adjusted Operating Income1 has improved by 20.2% 24.0% of sales 36.4 18.1% of sales 5.3 125.2 94.1 Reported EBIT Bayer Settlement PPA Recurring in € million H1 2009 Adjusted EBIT + 20.2% (16.2)% 2009 as reported H1 2009 recurring adjusted H1 2010 20.4% of sales 18.9% of sales 8.3 113.2 104
Ipsen — JP Morgan 29th Annual Healthcare Conference (January 2011) on 6ix